syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Company profile
Ticker
SNDX
Exchange
Website
CEO
Briggs Morrison
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Syndax Securities Corporation • Syndax Limited • Syndax Europe B.V. ...
SNDX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
2 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
8-K
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
18 Mar 24
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
27 Feb 24
8-K
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
20 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Dec 23
Transcripts
SNDX
Earnings call transcript
2023 Q4
27 Feb 24
SNDX
Earnings call transcript
2023 Q3
2 Nov 23
SNDX
Earnings call transcript
2023 Q2
3 Aug 23
SNDX
Earnings call transcript
2023 Q1
8 May 23
SNDX
Earnings call transcript
2022 Q4
28 Feb 23
SNDX
Earnings call transcript
2022 Q3
3 Nov 22
SNDX
Earnings call transcript
2022 Q2
8 Aug 22
SNDX
Earnings call transcript
2022 Q1
10 May 22
SNDX
Earnings call transcript
2021 Q4
2 Mar 22
SNDX
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Michael A Metzger
9 Feb 24
4
Keith A. Goldan
9 Feb 24
4
Neil Gallagher
9 Feb 24
4
Martin H. Jr. Huber
9 Feb 24
4
Jennifer Jarrett
9 Feb 24
4
Keith Katkin
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.77 mm | 94.77 mm | 94.77 mm | 94.77 mm | 94.77 mm | 94.77 mm |
Cash burn (monthly) | 908.33 k | (no burn) | 18.79 mm | 16.17 mm | 14.88 mm | 11.85 mm |
Cash used (since last report) | 6.02 mm | n/a | 124.50 mm | 107.19 mm | 98.65 mm | 78.51 mm |
Cash remaining | 88.75 mm | n/a | -29.74 mm | -12.43 mm | -3.88 mm | 16.26 mm |
Runway (months of cash) | 97.7 | n/a | -1.6 | -0.8 | -0.3 | 1.4 |
Institutional ownership, Q3 2023
92.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 180 |
Opened positions | 22 |
Closed positions | 11 |
Increased positions | 76 |
Reduced positions | 59 |
13F shares | Current |
---|---|
Total value | 1.02 tn |
Total shares | 78.60 mm |
Total puts | 3.33 mm |
Total calls | 3.78 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Wellington Management | 7.64 mm | $110.97 bn |
BLK Blackrock | 5.88 mm | $85.42 bn |
Vanguard | 3.62 mm | $52.52 bn |
STT State Street | 3.60 mm | $52.28 bn |
Kynam Capital Management | 3.60 mm | $52.27 bn |
Avidity Partners Management | 2.82 mm | $40.96 bn |
Partner Fund Management | 2.72 mm | $39.43 bn |
Access Industries | 2.60 mm | $41.19 mm |
Eversept Partners | 2.60 mm | $37.70 bn |
Avoro Capital Advisors | 2.56 mm | $37.11 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Aug 23 | Morrison Briggs | Common Stock | Sell | Dispose S | No | No | 18.2651 | 52,855 | 965.40 k | 17,836 |
9 Aug 23 | Morrison Briggs | Common Stock | Option exercise | Acquire M | No | No | 8.77 | 52,855 | 463.54 k | 70,691 |
9 Aug 23 | Morrison Briggs | Stock Options Common Stock | Option exercise | Dispose M | No | No | 8.77 | 52,855 | 463.54 k | 0 |
2 Aug 23 | William Meury | Common Stock | Sell | Dispose S | No | No | 20.4547 | 24,000 | 490.91 k | 48,000 |
2 Aug 23 | William Meury | Common Stock | Option exercise | Acquire M | No | No | 9.47 | 24,000 | 227.28 k | 72,000 |
2 Aug 23 | William Meury | Common Stock | Sell | Dispose S | No | No | 20.4563 | 24,000 | 490.95 k | 48,000 |
2 Aug 23 | William Meury | Common Stock | Option exercise | Acquire M | No | No | 7.88 | 24,000 | 189.12 k | 72,000 |
2 Aug 23 | William Meury | Common Stock | Sell | Dispose S | No | No | 20.4556 | 35,000 | 715.95 k | 48,000 |
2 Aug 23 | William Meury | Common Stock | Option exercise | Acquire M | No | No | 7.11 | 35,000 | 248.85 k | 83,000 |
2 Aug 23 | William Meury | Stock Options Common Stock | Option exercise | Dispose M | No | No | 7.11 | 35,000 | 248.85 k | 0 |
News
Syndax Pharmaceuticals Announced The Presentation Of Data From AUGMENT-101 Trial In Pediatric Patients With Relapsed/Refractory KMT2A-rearranged Acute Myeloid Leukemia And Acute Lymphoid Leukemia Treated With Revumenib
8 Apr 24
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
28 Mar 24
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
27 Mar 24
Syndax Reports FDA Priority Review Of NDA For Revumenib For Treatment Of Relapsed/Refractory KMT2Ar Acute Leukemia
26 Mar 24
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $34
20 Mar 24
Press releases
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
10 Apr 24
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
8 Apr 24
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5 Apr 24
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
28 Mar 24
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
28 Mar 24